1. Home
  2. RGNX vs SCM Comparison

RGNX vs SCM Comparison

Compare RGNX & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGNX
  • SCM
  • Stock Information
  • Founded
  • RGNX 2008
  • SCM 2012
  • Country
  • RGNX United States
  • SCM United States
  • Employees
  • RGNX N/A
  • SCM N/A
  • Industry
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • SCM Finance/Investors Services
  • Sector
  • RGNX Health Care
  • SCM Finance
  • Exchange
  • RGNX Nasdaq
  • SCM Nasdaq
  • Market Cap
  • RGNX 372.1M
  • SCM 361.0M
  • IPO Year
  • RGNX 2015
  • SCM 2012
  • Fundamental
  • Price
  • RGNX $7.57
  • SCM $14.45
  • Analyst Decision
  • RGNX Strong Buy
  • SCM Hold
  • Analyst Count
  • RGNX 12
  • SCM 2
  • Target Price
  • RGNX $35.55
  • SCM $13.63
  • AVG Volume (30 Days)
  • RGNX 1.8M
  • SCM 116.4K
  • Earning Date
  • RGNX 02-25-2025
  • SCM 03-03-2025
  • Dividend Yield
  • RGNX N/A
  • SCM 11.11%
  • EPS Growth
  • RGNX N/A
  • SCM 307.51
  • EPS
  • RGNX N/A
  • SCM 1.96
  • Revenue
  • RGNX $84,327,000.00
  • SCM $107,143,385.00
  • Revenue This Year
  • RGNX $2.92
  • SCM $0.34
  • Revenue Next Year
  • RGNX $256.82
  • SCM N/A
  • P/E Ratio
  • RGNX N/A
  • SCM $7.35
  • Revenue Growth
  • RGNX N/A
  • SCM 5.88
  • 52 Week Low
  • RGNX $6.56
  • SCM $12.48
  • 52 Week High
  • RGNX $28.80
  • SCM $14.68
  • Technical
  • Relative Strength Index (RSI)
  • RGNX 45.51
  • SCM 73.06
  • Support Level
  • RGNX $6.98
  • SCM $13.50
  • Resistance Level
  • RGNX $7.70
  • SCM $13.80
  • Average True Range (ATR)
  • RGNX 0.54
  • SCM 0.17
  • MACD
  • RGNX 0.04
  • SCM 0.08
  • Stochastic Oscillator
  • RGNX 44.30
  • SCM 100.00

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. Business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Share on Social Networks: